When was Group Pharmaceuticals Limited incorporated?

Group Pharmaceuticals Limited was incorporated in 1980 in Thane, Maharashtra under CIN U24239MH1980PLC022889, making it over 44 years old as of 2024.

Is Group Pharmaceuticals Limited listed on a stock exchange?

No. Group Pharmaceuticals Limited carries a 'U' (unlisted) CIN prefix, indicating it has never been listed on a stock exchange. Its shares trade only in the OTC/unlisted market at approximately ₹55 per share.

How do I buy Group Pharmaceuticals Limited unlisted shares here?

Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.

Who am I actually transacting with?

You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.

How do I pay, and is there a payment gateway?

Payment is by direct bank transfer to Prospire Network Private Limited's published account (CIN U82300UP2025PTC233622), shown to you in-app at the payment step. There is no card gateway and no escrow. Never pay to a personal account or to any account shared over phone, WhatsApp or email — even if the person claims to be from our team.

How long does settlement take?

After you accept an allocation, you have a short window to pay (typically 2 days). Once payment is verified, shares are usually credited to your demat within 2–3 business days, subject to depository timelines and any company-level restrictions. Timeframes are typical, not guaranteed.

There are no separate platform fee lines and no GST on the transfer — the desk's margin is built into the buy/sell price you're quoted. The only statutory add-on on a purchase is stamp duty on the consideration, shown transparently in your cost breakdown.

Is there a minimum ticket size for Group Pharmaceuticals Limited?

Minimums vary by company and depend on the lot the desk can source. Raise an enquiry and the desk will confirm the available quantity and the minimum for that name.

What KYC do I need, and do I need a demat account?

You'll share your demat details when you enquire so we can settle directly. Full KYC — PAN and a client-master / demat statement — is required before the transfer step, when shares actually change hands. Yes, you need an active demat account to hold unlisted shares.

Are there lock-ins on unlisted or pre-IPO shares?

Some shares carry statutory or company-imposed lock-ins — for example, a post-listing lock-in on pre-IPO stock — and transfers can be subject to the company's articles or approvals. Where a lock-in applies, we'll flag it before you commit.

How do I sell Group Pharmaceuticals Limited shares I already hold?

Raise a sell enquiry with the company, quantity and your target price. The desk confirms a buying price, you transfer your shares into the desk's demat, and once the credit is verified we pay you out by bank transfer to your registered account. The desk never pays out before your shares are received.

Unlisted shares are illiquid, may be hard or impossible to sell, and are not covered by exchange settlement guarantees or investor-protection funds. Pricing is indicative, not live. Read the full Risk Disclosure before you enquire, and invest only what you can afford to lock away.

Group Pharmaceuticals Limited Unlisted Share Price | Buy Group Pharmaceuticals Limited Pre-IPO Shares — wisefolio

Unlisted shares are illiquid and carry higher risk than listed securities. Prices are indicative, not live. Read the risk disclosure.

Talk to us

Group Pharmaceuticals Limited Unlisted Share Price | Buy Group Pharmaceuticals Limited Pre-IPO Shares — wisefolio | wisefolio

Investment Thesis

Group Pharmaceuticals Limited is a 1980-incorporated Thane-based pharmaceutical manufacturer specialising in oral care and dental solutions. With 44 years of operational history and a ₹55 unlisted share price, the company represents an established niche pharmaceutical player in India's growing dental health market. The oral care market's premiumisation and the expanding dental clinic network in India provide positive demand tailwinds. However, intense competition from Colgate, HUL, Dabur, and Himalaya — all with far greater distribution and marketing firepower — significantly constrains the company's market share growth potential. Investors should verify current product portfolio, distribution reach, and financial health through MCA records before any investment decision.

Pros

ISIN INE919X01015 confirmed; revenue ₹168 Cr (FY25) growing at 10% CAGR — substantial unlisted pharma manufacturer.
45+ years of pharmaceutical manufacturing since 1980; niche oral care specialization for dental and oral conditions.
MIDC Tarapur Industrial Area, Thane — established pharma manufacturing hub with regulatory infrastructure.
Authorized ₹25 Cr; paid-up ₹12.68 Cr — reasonable equity base relative to ₹168 Cr revenue.

Cons

Unlisted (U-prefix) — no secondary market despite 45 years of operations and ₹168 Cr revenue.
EBITDA CAGR only 1% despite 10% revenue growth — margin compression; rising input or operating costs.
Niche oral care pharma faces competition from multinationals (Colgate-Palmolive, GSK, P&G) and large domestic players.
No details on product brands or distribution network; governance transparency limited for a private company.

Business Segments

Oral Care Pharmaceuticals

Manufacturing of niche oral care pharmaceutical products targeting specific dental and oral health conditions; MIDC Tarapur manufacturing base.

Revenue Model

Group Pharmaceuticals Limited generates revenue through: (1) Manufacturing and sale of oral care and dental pharmaceutical products through wholesale distributors, pharmaceutical stockists, and pharmacy chains across Maharashtra and potentially other states; (2) Professional dental product sales to dental clinics, dentists, and hospitals through medical representative networks; and (3) Contract or third-party manufacturing of oral care formulations for other brands. Revenue is driven by product volumes, brand acceptance, and distributor penetration depth.

Detailed Analysis

Growth outlookExpansion plans, industry tailwinds & headwinds12

Growth Plans

India oral care market premiumisation creating demand for therapeutic dental products

Expansion of professional dental product channels through growing dental clinic network

Potential licensing or white-label partnerships with larger pharmaceutical or FMCG companies

Rural oral care penetration driving volume growth in underserved markets

Industry Tailwinds

Recent Developments

India oral care market premiumisation trend

India's oral care market is witnessing a strong premiumisation trend — consumers are increasingly shifting from basic toothpastes to specialised products (sensitive teeth care, charcoal whitening, herbal dental care). This trend benefits specialised dental pharmaceutical companies that can offer differentiated therapeutic products.

2023–2024

Growth in dental clinic network creating professional product demand

India's dental clinic network has expanded rapidly with over 300,000 registered dentists and growing dental chains in urban markets. This expansion drives demand for professional dental products — consumables, therapeutic formulations, and clinic-use dental solutions — which specialised dental pharmaceutical companies are positioned to serve.

2023–2024

Comparable Companies

CompanyTypeTickerMkt Cap

Colgate-Palmolive (India) LimitedListedCOLPALLarge-cap

Dabur India LimitedListedDABURLarge-cap

Himalaya Wellness CompanyListedUnlistedLarge unlisted

Venkys (India) Limited (Pharmaceutical Division)ListedVENKEYSSmall-cap

Frequently Asked Questions

Group Pharmaceuticals Limited is a Thane, Maharashtra-based pharmaceutical company incorporated in 1980, specialising in oral care and dental solutions. Its product portfolio likely includes dental medications, therapeutic toothpastes, dental gels, mouthwashes, and specialised dental care products sold through chemists, dental clinics, and pharmacy chains. The company focuses on the intersection of pharmaceuticals and consumer dental health.

India's oral care market encompasses toothpaste, toothbrushes, mouthwash, dental floss, teeth whitening products, and specialised dental pharmaceutical products. The market is valued at approximately ₹18,000–20,000 crore and growing at 7–10% per annum. Growth is driven by rising awareness, dental healthcare expansion in Tier 2/3 cities, and increasing professional dental product usage. The dental pharmaceutical sub-segment — including therapeutic toothpastes, fluoride gels, and anti-microbial mouthwashes — is a niche but growing category.

As a pharmaceutical manufacturer in India, Group Pharmaceuticals Limited is subject to regulation by the Central Drugs Standard Control Organisation (CDSCO) and the Maharashtra Food and Drug Administration (FDA). Manufacturing pharmaceutical oral care products requires Drug Manufacturing Licences (Form 25/28) under the Drugs and Cosmetics Act, 1940. Compliance with GMP (Good Manufacturing Practices) guidelines is mandatory.

In the pharmaceutical context, dental solutions refer to medicated or therapeutic oral care products: antiseptic mouthwashes (e.g. chlorhexidine-based), desensitising toothpastes (for sensitive teeth — potassium nitrate or strontium chloride formulations), fluoride dental gels, anti-fungal oral rinses, and prescription-grade dental topicals. These differ from standard consumer toothpastes as they contain active pharmaceutical ingredients (APIs) and may require pharmacy-only distribution.

About Group Pharmaceuticals Limited

Group Pharmaceuticals Limited is a Maharashtra-based pharmaceutical manufacturer incorporated on 24 July 1980, specialising in oral care and dental solutions. With CIN U24239MH1980PLC022889, the company has been operating for over four decades from its MIDC Tarapur facility in Thane, Maharashtra. The company reports revenue in the Rs 150-200 crore range with strong EBITDA growth of 82.5% YoY and net profit growth of 120.66%. The company holds a strategic 13.5% stake in bonyf NV, a European dental care company, reflecting its international orientation in the oral care segment. Group Pharmaceuticals is debt-free with a promoter holding of 62.02%, indicating strong insider confidence. It operates across 21 locations in India and serves both domestic and export markets for oral care products. With India's oral healthcare market growing rapidly amid increased dental health awareness, Group Pharmaceuticals is well-positioned in a specialised niche. The company's focus on oral care – toothpastes, dental solutions, mouthwashes, and related products – provides defensible market positioning. Its clean balance sheet (debt-free) and strong profitability growth make it one of the more financially attractive companies in this batch.

Key Milestones

Incorporated July 24, 1980 in Mumbai, Maharashtra (CIN: U24239MH1980PLC022889) — 45 years old

ISIN INE919X01015; Attavar family management; niche oral care pharma

Common questions about unlisted shares

How do I buy Group Pharmaceuticals Limited unlisted shares here?
Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.
Who am I actually transacting with?
You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.
How do I pay, and is there a payment gateway?

Risk factors & red flagsInvestment risks and items flagged from public filings11

Financial PerformanceLow

Net profit margin is thin at 3.4% (FY2024-25) — limited buffer against revenue or cost shocks

Source: Financial data

Fraud / GovernanceLow

India's oral care market is dominated by Colgate-Palmolive (40%+ market share), HUL, Dabur, Himalaya, and Patanjali — all with massive distribution networks, advertising budgets, and brand equity. A small unlisted pharmaceutical company has very limited ability to compete on brand awareness at scale.

Source: Media Reports / Public Records

Regulatory / LegalLow

Pharmaceutical manufacturing requires ongoing compliance with CDSCO and Maharashtra FDA regulations, including GMP audits, product licensing, and label compliance. Non-compliance can result in manufacturing license suspension and product recalls.

Source: Regulatory Filings

Fraud / GovernanceLow

Without access to national FMCG distribution networks, Group Pharmaceuticals is likely limited to regional Maharashtra distribution through pharmaceutical stockists and wholesale channels, capping revenue potential.

Source: Company Financial Filings

Fraud / GovernanceLow

No confirmed website, management details, or publicly available financial statements after 44 years of operations creates significant due diligence challenges.

Source: Media Reports / Public Records

Fraud / GovernanceLow

In consumer oral care, brand relevance requires consistent marketing investment. An unlisted company with limited capital access may struggle to maintain brand awareness against well-funded competition.

Source: Media Reports / Public Records

Competition Risk

Regulatory Compliance Risk

Distribution Limitation Risk

Information Risk

No confirmed website, management details, or publicly available financial statements after 44 years of operations creates significant due diligence challenges.

Brand Erosion Risk

Group Pharmaceuticals Limited

How settlement works

Get price alerts for Group Pharmaceuticals Limited

Discuss Group Pharmaceuticals Limited

Similar companies

Other ways to invest